DSS, Inc. has withdrawn its S-1 Registration Statement, prioritizing shareholder value and future financing opportunities.
Quiver AI Summary
DSS, Inc. has announced the withdrawal of its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission, citing an unfavorable market environment that does not align with the value the company aims to build for its shareholders. The decision, made by management and the Board of Directors, emphasizes DSS's commitment to accessing capital markets under terms that reflect the company's strategic plans. CEO Jason Grady reaffirmed that the company remains focused on executing its business plan and creating long-term shareholder value, while also evaluating alternative financing opportunities. The withdrawal of the registration statement does not indicate any change in the company’s business outlook or strategy, and DSS continues to pursue strategic initiatives such as the merger with Impact Biomedical aimed at unlocking value across its portfolio.
Potential Positives
- DSS, Inc. demonstrated strategic decision-making by withdrawing its Registration Statement on Form S-1, indicating a focus on shareholder value and market conditions.
- The company emphasizes its commitment to accessing capital at optimal times and terms, which positions it favorably for future financing opportunities.
- DSS continues to pursue strategic initiatives, including a merger with Impact Biomedical, which is expected to create long-term value for shareholders.
Potential Negatives
- The withdrawal of the Registration Statement may signal a lack of confidence from management regarding current market conditions, potentially reflecting negatively on the company's ability to attract capital.
- By choosing to postpone the offering, the company could be viewed as missing an opportunity to raise funds, which may hinder its strategic initiatives and growth ambitions.
- This decision to withdraw might create uncertainty among investors about the company's financial health and strategic direction, raising concerns about its long-term viability.
FAQ
Why did DSS withdraw its Registration Statement on Form S-1?
DSS withdrew its Registration Statement following a review of market conditions, determining the offering didn't reflect the company's value.
What is DSS's current strategy after withdrawing the registration?
The company plans to focus on executing its business plan and pursuing capital access when conditions are favorable.
Does the withdrawal indicate a negative outlook for DSS?
No, the withdrawal reflects strategic timing, not a change in business outlook or asset confidence.
What initiatives is DSS currently focusing on?
DSS is advancing several strategic initiatives, including a merger with Impact Biomedical to create long-term shareholder value.
How can investors contact DSS for more information?
Investors can contact DSS via email at [email protected] or call +1 (585) 565-2422 for inquiries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DSS Hedge Fund Activity
We have seen 7 institutional investors add shares of $DSS stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC added 32,090 shares (+144.2%) to their portfolio in Q1 2026, for an estimated $26,634
- CITADEL ADVISORS LLC added 19,443 shares (+inf%) to their portfolio in Q1 2026, for an estimated $16,137
- DRW SECURITIES, LLC removed 16,033 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $13,307
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 11,894 shares (+inf%) to their portfolio in Q1 2026, for an estimated $9,872
- TWO SIGMA SECURITIES, LLC added 10,164 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,436
- RENAISSANCE TECHNOLOGIES LLC added 5,794 shares (+18.4%) to their portfolio in Q1 2026, for an estimated $4,809
- TOWER RESEARCH CAPITAL LLC (TRC) added 2,403 shares (+87.0%) to their portfolio in Q1 2026, for an estimated $1,994
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) today announced that it has withdrawn its previously filed Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission. After careful review of current market conditions and deal terms, management and the Board of Directors concluded that proceeding with the offering at this time would not reflect the value DSS believes it is building for shareholders.
DSS remains well-positioned to access the capital markets and is committed to doing so at a time and on terms that are most conducive to the Company's strategic plan and that appropriately reflect the value of its business. The Company will continue to evaluate financing alternatives and capital markets opportunities as conditions develop.
"We are focused on executing our business plan and creating long-term value for our shareholders," said Jason Grady, Chief Executive Officer of DSS, Inc. "Accessing capital on the right terms, at the right time, is an important part of that discipline. We are confident in the direction of the Company and will pursue opportunities that align with where we are headed."
The withdrawal does not reflect any change in the Company’s business outlook, operating strategy, or confidence in the value of its assets and subsidiaries.
“DSS continues to believe there are significant opportunities across our businesses,” Grady added. "We remain focused on advancing several strategic initiatives, including the previously announced merger involving Impact Biomedical, which we believe has the potential to create meaningful long-term value for shareholders."
DSS continues to evaluate opportunities to unlock value across its portfolio while maintaining financial and strategic flexibility.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About DSS, Inc.
DSS, Inc. (NYSE American: DSS) is a multinational company operating across multiple business lines including product packaging, biotechnology, commercial lending, and securities and investment management. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit www.dssworld.com .
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks and uncertainties that may cause DSS's actual results to differ materially from those expressed or implied by such forward-looking statements. DSS undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Contact:
DSS, Inc.
Investor Relations
[email protected]
+1 (585) 565-2422
